focusIR May 2024 Investor Webinar: Blue Whale, Kavango, Taseko Mines & CQS Natural Resources. Catch up with the webinar here.
London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
Buys going through as sells.
Https://ondinebio.com/solutions/steriwave-healthcare/
Listen to the short video
Light-activated antimicrobial that does not generate antimicrobial resistance (AMR) approved for use in healthcare facilities operated by leading private healthcare provider HCA Healthcare UK Leading private healthcare provider, HCA Healthcare UK, has approved the Steriwave® light-activated antimicrobial developed by Ondine Biomedical Inc. (LON:OBI) for use in its healthcare facilities to prevent healthcare-associated infections (HAIs) and reduce the use of antibiotics. HCA Healthcare is the largest private healthcare provider in the world, and one of the leading private healthcare providers in the UK, where it operates over 30 healthcare facilities.
Antimicrobial resistance (AMR) is a growing concern for healthcare providers around the world, particularly in the prevention and treatment of HAIs. Steriwave is a light-activated antimicrobial with a distinct mechanism of action from traditional antibiotics, allowing it to be used without fear of generating AMR. Its broad-spectrum efficacy destroys bacteria, viruses, and fungi in a single, 5-minute treatment.
Steriwave has already been successfully used in a small patient population in HCA Healthcare UK hospitals, but this approval will allow additional hospitals and healthcare facilities to adopt the technology more widely at the discretion of the clinician.
Professor Claire Hopkins, Professor of Rhinology at King's College London and Consultant ENT Surgeon at Guy's & St Thomas' NHS Foundation Trust and London Bridge Hospital, has used Steriwave routinely to nasally decolonise her endoscopic sinus surgery patients at HCA Healthcare UK's London Bridge Hospital since 2021. A retrospective study showed that using Steriwave in endoscopic sinus surgery patients led to antibiotic use across all her patients dropping from 22% to less than 5% – a 77% reduction.
Professor Hopkins commented: "I was amazed that studies show that by treating the nose you can reduce spinal surgical site infections – so it seemed an ideal way to reduce the risk of post-operative infection after nasal surgery. I have seen a significant reduction in post-operative infections requiring antibiotics, which is good for the patients, reducing the risk of antibiotic-related side effects, and important to help prevent ever-increasing antibiotic resistance. It needs formal controlled studies to further evaluate the effectiveness, but I am impressed with the difference that I have seen in my practice."
Interview with Professor Hopkins: Steriwave prevents sinonasal SSIs (https://ondinebio.com/media/steriwave-prevents-sinonasal-ssis/?portfolioCats=68)
Carolyn Cross, Ondine Biomedical CEO, commented: "We are delighted that Steriwave has now been authorized for use across HCA Healthcare UK's healthcare facilities. We are already working closely with HCA Healthcare in the US on our US Phase 3 trial and the FDA regulatory submission for Steriwave, so it is fantastic to be getting such good support from them in the UK as we
Patients in West Yorkshire have become the first in the country to access a new pre-surgery laser treatment, following a successful trial.
Mid Yorkshire Teaching NHS Trust has started to roll out Steriwave on those coming in for hip and knee surgery.
The treatment involves a probe shining a red light into patients' nostrils to kill off bacteria which cause surgical site infections.
Dr Stuart Bond called it an "important new technology".
"We are very excited to be the first Trust to be giving patients access to this important new technology which kills viruses, bacteria, and fungi with a five-minute treatment," Dr Bond, a consultant antimicrobial pharmacist and director of innovation, said.
The treatment was rolled out following a successful trial at Pontefract Hospital last year, with the aim of helping to prevent patients getting infections during surgery.
The NHS has previously said it hopes it could be an alternative to nasal antibiotics, which are currently given to patients before their surgery to prevent infections such as MRSA.
Carolyn Cross, chief executive officer at Ondine Biomedical, said: "We are delighted the Trust has adopted Steriwave, particularly as the NHS is seen around the world as a leader in antibiotic stewardship in response to the growing threat of antimicrobial resistance."
Presentational grey line
Follow BBC Yorkshire on Facebook, X (formerly T
7.03-7.20p
current price
so just bought more
Earlier this week, the innovative work being done with Steriwave at the Mid Yorkshire Teaching NHS Trust was the focus of a BBC news article. This coverage offers a moment to acknowledge the commitment and expertise of the teams at Pontefract and Pinderfields hospitals, whose contributions are at the heart of these advancements.
It is a privilege to see our collaborative efforts in enhancing surgical safety and tackling antimicrobial resistance being recognized. The article delves into the details of this initiative and its significance, and I believe you'll find it both informative and reflective of the strides we're making together.
Simple Solutions
to Prevent Complex Infections
https://ondinebio.com/investors/reports-documentation/
Https://ondinebio.com/media/steriwave-prevents-sinonasal-ssis/?portfolioCats=68
Peterobert - I agree
For anyone wanting to listen to the 2 minute video by Prof Claire Hopkins here is the link
https://ondinebio.com/media/steriwave-prevents-sinonasal-ssis/?portfolioCats=68
Good News is worth repeating my friend !!!
Peterobert
You beat me to it. Sorry for duplicating the information
I received the following information from Ondine following the release of the RNS:
"We are very pleased as this procurement authorization facilitates the ability for HCA clinicians across the HCA UK network to adopt Steriwave to prevent healthcare-associated infections for their patients and reduce unnecessary antibiotic use. HCA UK has built a world-class network of over 30 facilities in London and Manchester, with its latest venture opened in Birmingham in 2023. HCA is the largest private healthcare provider in the world and one of the leading private healthcare providers in the UK. HCA Healthcare UK, is the only private hospital group in the UK to have the highest level of critical care beds in all of its facilities, and it positively takes on new challenges in innovation and advancing critical care. We believe our clinical work to advance the use of Steriwave into ICUs will be leveraged by this key procurement relationship in due course.
The procurement clearance at HCA UK, following the recent news of our first NHS hospital deployments in Mid Yorkshire, we believe bodes well for our growth goals."
Whilst I agree pricing details would be useful to fully consider the value of the company, I believe they are making steady progress and their relationship with HCA appears strong and could provide the opportunity for significant growth in the US. An update on progress of the Phase 3 trial is awaited with interest.
Earlier today, we announced further important inroads into the UK market alongside a deepening of our HCA relationship.
HCA Healthcare UK has approved Steriwave for use in its healthcare facilities, leveraging the positive experience and study findings from Professor Claire Hopkins, Professor of Rhinology at King's College London and Consultant ENT Surgeon at Guy's & St Thomas' NHS Foundation Trust. Professor Hopkins was the first to use presurgical nasal photodisinfection prior to sinus surgeries and demonstrated significant reductions in post-surgical infections and antibiotic use--a particular advantage in this patient population. You can see here speaking about her Steriwave experience and study findings here.
We are very pleased as this procurement authorization facilitates the ability for HCA clinicians across the HCA UK network to adopt Steriwave to prevent healthcare-associated infections for their patients and reduce unnecessary antibiotic use. HCA UK has built a world-class network of over 30 facilities in London and Manchester, with its latest venture opened in Birmingham in 2023. HCA is the largest private healthcare provider in the world and one of the leading private healthcare providers in the UK. HCA Healthcare UK, is the only private hospital group in the UK to have the highest level of critical care beds in all of its facilities, and it positively takes on new challenges in innovation and advancing critical care. We believe our clinical work to advance the use of Steriwave into ICUs will be leveraged by this key procurement relationship in due course.
The procurement clearance at HCA UK, following the recent news of our first NHS hospital deployments in Mid Yorkshire, we believe bodes well for our growth goals.
For more details, please read
RBC target 60p
Balanced
Spot on with your analysis
OBI have partners in USA for P3. "HCA Healthcare is partnering with Ondine in the United States to conduct a US Phase 3 clinical trial with the ultimate goal of obtaining FDA approval to bring Ondine's nasal photodisinfection into the US market. HCA Healthcare operates 184 hospitals and over 2,000 sites of care across the United States, making it the largest healthcare system in the US."
So costs may not be huge as HCA have many patients to participate.
Totally agree that there is so little information on pricing or volumes to make an informed decision. Use is broadening but if the margins are thin to attract business, the break even point may be some way off.
The product seems great. However the financial projections have not been provided such as pricing information, volume of sales, next 5 year sales, margins etc. It's possible that the hospitals coming on board have been receiving free product to date to sample and decide on whether to use on an ongoing basis. That may therefore explain the negligible revenues to date?
However, it's not easy to invest in this without any projections on turnover and margins and the road to profitability.
Funding is the key issue at the moment as it will run out of money soon.
Phase 3 trials are expensive and if they can't partner with someone to fund the trials in exchange for a proportion of the future profits then they might need to shelve the trial until funding can be secured at a future date. The FDA approval process is lengthy and time consuming so possibly looking at 12-24 months from when the phase 3 trial starts. However it has much of the ROW to go after so the commercial and marketing data is essential.
So when this dilutes you , will it is still be 60p target ?
Seems to be a relatively big move on share price with not many trades/volume?
Targe 60p
We hope that you have seen today's news release in which we announced that we are accelerating our efforts to expand into the Intensive Care Units (ICU) market due to growing interest from hospitals. The ICU market substantially increases our target market and, more importantly, we believe, can accelerate hospital adoption given the infection problem in all ICUs. Expanding use within our current hospitals can be a significant growth factor as well as improving time to new hospital adoption.
We need to be in the ICU—patients in ICUs are at high risk for healthcare-acquired infections (HAI) due to the high prevalence of invasive procedures and devices. ICUs are where the most vulnerable and immunocompromised patients are found. Because nasal decolonization has been shown to reduce ICU infection rates in other studies, we believe that our broad-spectrum Steriwave® can really make a difference reducing the infection rates—and therefore the mortality rates.
One in every eight ICU patients in Canada suffers from infections not related to their original illness and acquired in the hospital when their immune systems are down. Mortality rates are highest in the ICU as a result. With ICU mortality rates at 9% in North America and up to 18% in Europe, we need to be saving more lives sooner. So, we have made the decision to accelerate our ICU clinical pilot work and look forward to updating you in the quarters ahead on this progress.
You might miss out
just my opinion - always research first